Connect with us

Health

Commission invests in the development of innovative products against respiratory viruses

SHARE:

Published

3 weeks ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Commission, with the support of the European Investment Bank, will provide €20 million in the development of nasal sprays designed to protect against respiratory viruses. For this purpose, the Commission through its Health Emergency Preparedness and Response Authority (HERA), has signed an investment agreement with the Dutch biotech company Leyden Labs. 

The nasal spray delivers antibodies directly into the nasal cavity, stopping infections at the point of entry, and potentially preventing onward transmission. By targeting commonalities among virus families, rather than one variant in particular, this innovative approach provides broad protection against various existing and new viruses. The technology provides a universal solution to respiratory viruses, regardless of an individual's immune history – for example, people who do not sufficiently respond to a vaccine, or don't get vaccinated.

Equality, Preparedness and Crisis Management Commissioner Hadja Lahbib (pictured) said: “Respiratory viruses are common and affect us all, especially the most medically vulnerable. Today's agreement reaffirms our commitment to invest in innovation to strengthen preparedness and protection against respiratory viruses. HERA Invest is a prime example of Europe at the forefront of medical advancements in response to serious threats to health.”

HERA Invest is a flagship initiative designed to enhance Europe's strategic autonomy in health emergency preparedness. Backed by €110 million from the EU4Health programme as part of the InvestEU initiative, it targets small and mid-sized companies. The European Investment Bank in partnership with HERA, provides venture loans covering up to 50% of a project's costs. HERA Invest aims to bridge the financial gap where private sector resources are insufficient, leveraging public funds to encourage private investment in the development of medical countermeasures. By supporting research and development in these areas, HERA Invest seeks to ensure that Europe remains prepared to face future health challenges.

Share this article:

Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending